NanoART, neuroAIDS and CNS drug delivery

Sustained-release nanoART formulation for the treatment of neuroAIDS

A novel approach was developed for the coencapsulation of an anti-HIV drug (tenofovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL) assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe3O4) nanoparticles (10±3 nm) were synthesized and characterized. The LbL technique was used to achieve a sustained release profile, and appl...

Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier

Present review highlights various drug delivery systems used for delivery of pharmaceutical agents mainly antibiotics, antineoplastic agents, neuropeptides, and other therapeutic substances through the endothelial capillaries (BBB) for CNS therapeutics. In addition, the use of ultrasound in delivery of therapeutic agents/biomolecules such as proline rich peptides, prodrugs, radiopharmaceuticals...

CNS as an HIV-1 reservoir; BBB and drug delivery.

In September of last year, the National Institute of Neurological Disorders and Stroke (NINDS) sponsored an AIDS Program Panel meeting entitled `CNS as an HIV-1 Reservoir: BBB and Drug Delivery'. The main objective of this highly focused meeting was to discuss the latest understandings of systemic drug delivery to the brain and the dif®culties which may be associated with developing optimal tre...

Model of NeuroAIDS Antiretroviral Drug to the Brain in a Murine Macrophage Delivery of Nanoformulated

Opiate Drug Use and the Pathophysiology of NeuroAIDS

Opiate abuse and HIV-1 have been described as interrelated epidemics, and even in the advent of combined anti-retroviral therapy, the additional abuse of opiates appears to result in greater neurologic and cognitive deficits. The central nervous system (CNS) is particularly vulnerable to interactive opiate-HIV-1 effects, in part because of the unique responses of microglia and astroglia. Althou...